![Ulrich Granzer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ulrich Granzer
Director Ejecutivo en
Granzer Regulatory Consulting & Services
.
Perfil
Ulrich Granzer is the founder of Granzer Regulatory Consulting & Services, which was founded in 2002.
He is currently the Director at Cardior Pharmaceuticals GmbH, a Venture Partner at Wellington Partners GmbH since 2004, and a Member-Supervisory Board at APEIRON Biologics AG since 2021.
Dr. Granzer previously served as the Chairman-Supervisory Board at Biofrontera AG from 2016 to 2021.
He also held positions as Director of Regulatory Affairs at Bayer AG, GSK Plc, and Knoll AG.
Additionally, he was a Director-Supervisory Board at Immatics Biotechnologies GmbH from 2009 to 2012 and Head of Regulatory Affairs at Bayer Pharma AG.
Dr. Granzer holds a doctorate degree from Eberhard Karls Universität Tübingen and a graduate degree from Philipps University of Marburg.
Cargos activos de Ulrich Granzer
| Empresas | Cargo | Inicio |
|---|---|---|
Granzer Regulatory Consulting & Services | Director Ejecutivo | 01/01/2002 |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Director/Miembro de la Junta | - |
APEIRON Biologics AG
 APEIRON Biologics AG BiotechnologyHealth Technology Develops therapies for cancer immunotherapy and respiratory diseases | Director/Miembro de la Junta | 21/06/2021 |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners invests in companies located in Europe, the United States and Asia. The firm focuses on biotechnology, therapeutics, medical devices, diagnostics and digital health sectors. It provides financing for early and growth stage transactions with an investments size of EUR 2 - 20 million. The firm also acts as lead investor. | Inversor de Capital Privado | 01/01/2004 |
Antiguos cargos conocidos de Ulrich Granzer.
| Empresas | Cargo | Fin |
|---|---|---|
| BIOFRONTERA AG | Presidente | 14/12/2021 |
| BAYER AG | Consejero General | - |
Knoll AG
 Knoll AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Consejero General | - |
| GSK PLC | Consejero General | - |
Bayer Pharma AG
 Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Consejero General | - |
Formación de Ulrich Granzer.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
75
Relaciones de 1er grado
12
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 12 |
|---|---|
Bayer AG
 Bayer AG Pharmaceuticals: MajorHealth Technology Provides health care, nutrition and high-tech material services | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners invests in companies located in Europe, the United States and Asia. The firm focuses on biotechnology, therapeutics, medical devices, diagnostics and digital health sectors. It provides financing for early and growth stage transactions with an investments size of EUR 2 - 20 million. The firm also acts as lead investor. | Finance |
Biofrontera AG
 Biofrontera AG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops and distributes dermatological products | Health Technology |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
Eberhard Karls Universität Tübingen
 Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Philipps University of Marburg
 Philipps University of Marburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology Develops therapies for cancer immunotherapy and respiratory diseases | Health Technology |
Granzer Regulatory Consulting & Services | |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Health Technology |
- Bolsa de valores
- Insiders
- Ulrich Granzer
